# Precision Medicine for Patients With Identified Actionable Mutations

> **NCT04111107** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 45 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma
- Multiple Myeloma
- Malignant Neoplasm
- Mutation Abnormality

## Interventions

- **DRUG:** Investigational Agent
- **OTHER:** Supportive Care Regimens
- **DIAGNOSTIC_TEST:** Next Gen Sequencing Report

## Key facts

- **NCT ID:** NCT04111107
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-22
- **Primary completion:** 2022-12-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** PI left the institution and site decided not to continue the study
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04111107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04111107, "Precision Medicine for Patients With Identified Actionable Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04111107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*